新辅助化疗联合D2胃切除术后胃腺癌分期系统的开发与验证
本研究基于纪念斯隆凯特琳癌症中心325例接受新辅助化疗后D2胃切除术的胃腺癌患者开发改良ypTNM分期系统,并在186例国际队列中验证。改良系统可分类AJCC系统无法分类的ypT0N0/+肿瘤,5年OS区分度及C指数均优于AJCC第八版。
要点
- 验证队列中改良系统对OS的预后分层同样更优。
核心结论
- 改良ypTNM分期系统提高了新辅助化疗后D2胃切除术患者OS预测的准确性。
研究设计与样本
- 基于纪念斯隆凯特琳癌症中心325例接受新辅助化疗后D2胃切除术患者的OS开发改良ypTNM系统,并用186例国际队列验证。
主要发现
- 验证队列186例中,改良系统对OS的预后分组区分同样更好。
临床怎么用
- 对于接受新辅助化疗后D2胃切除术的局部进展期胃腺癌患者,可采用改良ypTNM分期进行更准确的OS预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy is commonly used for patients with locally advanced gastric adenocarcinoma. The eighth AJCC ypTNM staging system was validated based on patients undergoing more limited lymphadenectomy (less than D2). The aim of this study was to develop a system for accurate staging of patients with locally advanced gastric adenocarcinoma who receive neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy. METHODS: A modified system of ypTNM was developed, based on overall survival (OS) of patients receiving neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy at Memorial Sloan Kettering Cancer Center, and validated using data from an international cohort of patients who had similar treatment. RESULTS: Of 325 patients in the derivation cohort, 33 (10·2 per cent) had ypT0 N0/+ tumours, which are not classifiable under the AJCC system. The 5-year OS rate for modified ypTNM stages I, II, IIIA and IIIB was 89, 71, 42·3 and 10 per cent respectively, compared with 82, 65·2 and 24·1 for AJCC stages I, II and III respectively. The concordance index (0·730 versus 0·709), estimated area under the curve (0·765 versus 0·740) and time-dependent receiver operating characteristic (ROC) curve throughout the observation period were all superior for modified ypTNM staging. For the validation cohort of 186 patients, the modified system was again better at separating patients into prognostic groups for OS. CONCLUSION: The modified ypTNM staging system improves the accuracy of OS prediction for patients treated with neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy.
引用
- Lin JX, Yoon C, Desiderio J, et al. Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg. 2019. PMID: 31197829. doi:10.1002/bjs.11181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。